Ono Pharmaceutical Co. Ltd. has successfully completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. for $25.60 per share (total amount of approximately $2.4 billion), through its wholly-owned subsidiary, Topaz Merger Sub Inc.
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to a new SEC filing. In total, Deciphera reached out to 23 companies to gauge buyout interest. Ultimately, Deciphera was acquired by Ono for $25.60 per share in April. — Max Gelman
Japan`s Ono to buy US drugmaker Deciphera for $2.4 bln
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Deciphera Announces Fourth Quarter and Full Year 2023 Financial Results
Deciphera Pharmaceuticals to Present at the 6th Annual Biotechnology Conference